Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,8.5,169162,DB04892,Phenserine
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,12.6,169163,DB04892,Phenserine
>,11261809,half-life,"In contrast, a high (> 70%) and long-lasting inhibition of AChE was achieved (half-life > 8.25 h).",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),h,8.25,169164,DB04892,Phenserine
,11261809,oral bioavailability,A comparison between the time-dependent plasma AChE inhibition achieved after similar oral and i.v. doses provided an estimate of oral bioavailability of 100%.,The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),%,100,169165,DB04892,Phenserine
,16248851,MTD,The MTD of phenserine tartrate was 10 mg.,Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),mg,10,247715,DB04892,Phenserine
,16248851,Cmax,"Subjects receiving 10 mg of phenserine tartrate had a Cmax of 1.95 ng/mL at 1.5 hours, and the mean peak inhibition (Imax) of AChE was 26% (range: 18-34%) at 1.75 hours (tImax) following dosing.",Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),[ng] / [ml],1.95,247716,DB04892,Phenserine
,16248851,peak inhibition (Imax),"Subjects receiving 10 mg of phenserine tartrate had a Cmax of 1.95 ng/mL at 1.5 hours, and the mean peak inhibition (Imax) of AChE was 26% (range: 18-34%) at 1.75 hours (tImax) following dosing.",Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),%,26,247717,DB04892,Phenserine
,16248851,half-life of AChE inhibition (tI1/2),The half-life of AChE inhibition (tI1/2) was 11 hours.,Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),h,11,247718,DB04892,Phenserine
